\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes Defence NATO-EDA🚨Calling deep tech, dual-use innovators🚨
Interested in joining the DIANA programme?
We're excited to share that DIANA's latest Challenge Call will open next month. Successful candidates will become part of DIANA’s 2026 cohort of innovators.
DIANA formulates ‘Challenges’ based on the priorities of NATO Allied nations, the latest trends in emerging and disruptive technologies, and market potential.
Through DIANA’s Challenge Calls, innovators propose technologies that could address these challenges, which they then develop with feedback from end-users and potential buyers as they go through DIANA’s Accelerator Programme.
If you're an innovator with a game-changing technology that could help address some of the world’s most complex and profound security challenges, make sure you follow the DIANA website or the DIANA LinkedIn page for updates.
Also see the follwing events: https://ncpflanders.be/activities/diana-challenge-call-webinars-on-may-22nd-june-5th-and-19th
👉 Watch the video of the first webinar from 22 May: https://lnkd.in/dAT3_Uqw
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
